Your browser is no longer supported. Please, upgrade your browser.
Settings
BTX [AMEX]
Brooklyn ImmunoTherapeutics, Inc.
Index- P/E- EPS (ttm)-1.68 Insider Own11.40% Shs Outstand42.45M Perf Week-12.64%
Market Cap469.45M Forward P/E- EPS next Y- Insider Trans-7.01% Shs Float24.28M Perf Month-9.19%
Income-29.00M PEG- EPS next Q- Inst Own8.60% Short Float2.78% Perf Quarter-27.54%
Sales2.70M P/S173.87 EPS this Y-110.90% Inst Trans0.34% Short Ratio0.88 Perf Half Y-75.16%
Book/sh0.83 P/B10.24 EPS next Y- ROA-123.00% Target Price20.00 Perf Year102.38%
Cash/sh0.91 P/C9.35 EPS next 5Y- ROE-361.00% 52W Range3.50 - 80.67 Perf YTD89.73%
Dividend- P/FCF- EPS past 5Y17.40% ROI-217.30% 52W High-89.59% Beta4.74
Dividend %- Quick Ratio6.80 Sales past 5Y-25.00% Gross Margin49.30% 52W Low140.00% ATR0.56
Employees22 Current Ratio6.80 Sales Q/Q- Oper. Margin- RSI (14)34.92 Volatility5.53% 5.84%
OptionableYes Debt/Eq0.02 EPS Q/Q82.90% Profit Margin- Rel Volume0.58 Prev Close8.50
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume764.82K Price8.40
Recom- SMA20-6.85% SMA50-17.20% SMA200-33.47% Volume115,167 Change-1.18%
Oct-06-21Initiated Maxim Group Buy $20
Oct-27-21 07:05AM  
Oct-14-21 04:15PM  
Oct-07-21 10:11PM  
Sep-23-21 04:30PM  
Sep-22-21 10:07AM  
Sep-21-21 08:30AM  
Sep-15-21 08:15AM  
Sep-13-21 08:00AM  
Sep-09-21 08:30AM  
Aug-20-21 04:15PM  
08:30AM  
Aug-16-21 04:15PM  
08:30AM  
07:00AM  
Aug-13-21 02:22PM  
Jul-23-21 04:30PM  
Jul-19-21 08:00AM  
Jul-13-21 08:15AM  
Jul-12-21 08:15AM  
Jul-08-21 11:20AM  
Jul-06-21 05:57PM  
Jun-14-21 07:30AM  
Jun-09-21 07:30AM  
Jun-08-21 07:30AM  
Jun-02-21 08:00AM  
May-26-21 02:03PM  
May-24-21 02:58PM  
May-21-21 07:30AM  
May-18-21 07:30AM  
May-11-21 07:30AM  
May-07-21 07:30AM  
Apr-29-21 07:30AM  
Apr-26-21 07:30AM  
Apr-19-21 04:10PM  
Apr-15-21 04:10PM  
08:00AM  
Apr-06-21 08:00AM  
Mar-25-21 05:20PM  
Dec-14-20 08:44AM  
Nov-04-20 06:05PM  
May-08-20 10:37PM  
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENNY GEORGE P III10% OwnerJul 14Buy11.991123Aug 20 01:38 PM
DENNY GEORGE P III10% OwnerJul 09Buy14.111142Aug 20 01:38 PM
DENNY GEORGE P III10% OwnerJul 08Buy14.351141Aug 20 01:38 PM
DENNY GEORGE P III10% OwnerJul 06Sale16.0675,0001,204,6884,775,117Aug 20 01:38 PM
Cherington CharlesDirectorJun 17Sale15.75200,0003,149,8085,894,101Jun 21 06:00 PM
Cherington CharlesDirectorJun 16Sale15.73200,0003,146,7606,094,101Jun 21 06:00 PM